0 Comment
The Hague, June 23 (EFE).- The European Medicines Agency (EMA) on Friday denied authorizing the marketing of Albrioza, a treatment for amyotrophic lateral sclerosis (ALS), considering that it has not been proven that this drug really delays the worsening of this neurological disease. At its monthly meeting, the Committee for Medicinal Products for Human Use... Read More